Measles Rubella (MR) Vaccine

MR vaccine targets measles and rubella. India launched a national MR campaign in 2017 to vaccinate all children 9 months to 15 years, contributing to measles elimination goals.

The Measles Rubella (MR) Vaccine is recommended for 9 months to 15 years (campaign); 9–12 months (routine). It falls under the Booster vaccine category. Consult your doctor to confirm if this vaccine is right for you based on your health history and existing immunity.

The Measles Rubella (MR) Vaccine has an efficacy of 95–97% effective against measles and rubella after 2 doses. This means it provides significant protection against Measles and Rubella. Efficacy may vary based on age, health status, and the specific strain encountered.

Common side effects include: Mild fever; rash at 7–12 days post-vaccination. Transient joint pain (rubella component).. These are typically mild and resolve within 1–3 days. Serious allergic reactions are rare — if you experience difficulty breathing, hives, or rapid heartbeat after vaccination, seek emergency care immediately.

The Measles Rubella (MR) Vaccine should be avoided by: Pregnancy; severe immunosuppression; allergy to neomycin.. Always inform your healthcare provider of your full medical history before vaccination.

The Measles Rubella (MR) Vaccine typically costs Free under UIP; ₹200–₹350 private in India. Government health centres may offer it free or at subsidised prices for eligible age groups. Private hospitals and clinics may charge differently. Additional fees may apply for administration.